BNTX vs IPHA
BioNTech SE and Innate Pharma SA, side by side — 9 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BNTX | IPHA |
|---|---|---|
| Revenue | €2.9B | €9.0M |
| Net income | €-1.1B | €-49.2M |
| Gross margin | 77.6% | — |
| Net margin | −39.6% | −546.1% |
| Return on equity | 3.1% | — |
| Diluted EPS | −€4.70 | −€0.55 |
| Dividend / share | — | — |
| Payout ratio | −0.0% | — |
| Free cash flow | €280.9M | €-52.9M |
| Equity | €493.5M | — |
| Net debt / equity | — | — |
| Current ratio | 7.54× | 1.27× |
| Revenue CAGR 5y | 42.9% | −33.6% |
| Profit CAGR 5y | — | — |
BNTX bills 318.7× the revenue of IPHA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
9 years side by side
| Fiscal year | BNTX | IPHA |
|---|---|---|
| FY2025 | €2.9B | €9.0M |
| FY2024 | €2.8B | €20.1M |
| FY2023 | €3.8B | €61.6M |
| FY2022 | €17.3B | €57.7M |
| FY2021 | €19.0B | €24.7M |
| FY2020 | €482.3M | €69.8M |
| FY2019 | €108.6M | €85.4M |
| FY2018 | €127.6M | €94.0M |
| FY2017 | €61.6M | €44.0M |
Net income by year
Bottom line
| Fiscal year | BNTX | IPHA |
|---|---|---|
| FY2025 | €-1.1B | €-49.2M |
| FY2024 | €-665.3M | €-49.5M |
| FY2023 | €930.3M | €-7.6M |
| FY2022 | €9.4B | €-58.1M |
| FY2021 | €10.3B | €-52.8M |
| FY2020 | €15.2M | €-64.0M |
| FY2019 | €-179.1M | €-20.8M |
| FY2018 | €-48.0M | €3.0M |
| FY2017 | €-85.7M | €-48.4M |
Advertisement
AdSense · Rectangle 336×280
More in this industry